Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 5604891, 16 pages
https://doi.org/10.1155/2017/5604891
Review Article

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

1Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
2CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
3Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France
4CHU Nantes, Hotel Dieu, Nantes, France
5Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, USA

Correspondence should be addressed to Stéphane Birklé

Received 15 August 2016; Revised 18 November 2016; Accepted 8 December 2016; Published 5 January 2017

Academic Editor: Julie Boucau

Copyright © 2017 Julien Fleurence et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Svennerholm, “Composition of gangliosides from human brain,” Nature, vol. 177, no. 4507, pp. 524–525, 1956. View at Publisher · View at Google Scholar · View at Scopus
  3. R. K. Yu, Y.-T. Tsai, T. Ariga, and M. Yanagisawa, “Structures, biosynthesis, and functions of gangliosides-an overview,” Journal of Oleo Science, vol. 60, no. 10, pp. 537–544, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. K. Yu, M. Ynagisawa, and T. Ariga, “Glycosphingolipid structures,” in Comprehensive Glycoscience, pp. 73–122, Elsevier, Oxford, UK, 2007. View at Google Scholar
  5. D. A. Cheresh, R. A. Reisfeld, and A. P. Varki, “O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant,” Science, vol. 225, no. 4664, pp. 844–846, 1984. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Chammas, J. L. Sonnenburg, N. E. Watson et al., “De-N-acetyl-gangliosides in humans: unusual subcellular distribution of a novel tumor antigen,” Cancer Research, vol. 59, no. 6, pp. 1337–1346, 1999. View at Google Scholar · View at Scopus
  7. B. L. Slomiany, K. Kojima, Z. Banas‐Gruszka, V. L. N. Murty, N. I. Galicki, and A. Slomiany, “Characterization of the sulfated monosialosyltriglycosylceramide from bovine gastric muscosa,” European Journal of Biochemistry, vol. 119, no. 3, pp. 647–650, 1981. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Ando, R. K. Yu, J. N. Scarsdale, S. Kusunoki, and J. H. Prestegard, “High resolution proton NMR studies of gangliosides. Structure of two types of GD3 lactones and their reactivity with monoclonal antibody R24,” The Journal of Biological Chemistry, vol. 264, no. 6, pp. 3478–3483, 1989. View at Google Scholar · View at Scopus
  9. H. Iber, C. Zacharias, and K. Sandhoff, “The c-series gangliosides GT3, GT2 and GP1C are formed in rat liver golgi by the same set of glycosyltransferases that catalyse the biosynthesis of asialo-, a- and b-series gangliosides,” Glycobiology, vol. 2, no. 2, pp. 137–142, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. P. M. Crespo, R. Iglesias-Bartolomé, and J. L. Daniotti, “Ganglioside GD3 traffics from the trans-Golgi network to plasma membrane by a Rab11-independent and brefeldin A-insensitive exocytic pathway,” The Journal of Biological Chemistry, vol. 279, no. 46, pp. 47610–47618, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sonnino, L. Mauri, V. Chigorno, and A. Prinetti, “Gangliosides as components of lipid membrane domains,” Glycobiology, vol. 17, no. 1, pp. 1R–13R, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S.-I. Hakomori, “The glycosynapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 225–232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Birklé, G. Zeng, L. Gao, R. K. Yu, and J. Aubry, “Role of tumor-associated gangliosides in cancer progression,” Biochimie, vol. 85, no. 3-4, pp. 455–463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Feizi, “Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens,” Nature, vol. 314, no. 6006, pp. 53–57, 1985. View at Publisher · View at Google Scholar · View at Scopus
  15. G. A. Lammie, N.-K. V. Cheung, W. Gerald, M. Rosenblum, and C. Cordon-Cardo, “Ganglioside GD2 expression in the human nervous system and in neuroblastomas—an immunohistochemical study,” International Journal of Oncology, vol. 3, no. 5, pp. 909–915, 1993. View at Google Scholar · View at Scopus
  16. C. Martinez, T. J. Hofmann, R. Marino, M. Dominici, and E. M. Horwitz, “Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs,” Blood, vol. 109, no. 10, pp. 4245–4248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Z.-L. Wu, E. Schwartz, R. Seeger, and S. Ladisch, “Expression of GD2 ganglioside by untreated primary human neuroblastomas,” Cancer Research, vol. 46, no. 1, pp. 440–443, 1986. View at Google Scholar · View at Scopus
  18. T. Watanabe, C. S. Pukel, H. Takeyama et al., “Human melanoma antigen AH is an autoantigenic ganglioside related to GD2,” Journal of Experimental Medicine, vol. 156, no. 6, pp. 1884–1889, 1982. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Cheresh, J. Rosenberg, K. Mujoo, L. Hirschowitz, and R. A. Reisfeld, “Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis,” Cancer Research, vol. 46, no. 10, pp. 5112–5118, 1986. View at Google Scholar · View at Scopus
  20. H. D. Mennel, K. Bosslet, H. Wiegandt, H. H. Sedlacek, B. L. Bauer, and A. F. Rodden, “Expression of GD2-epitopes in human intracranial tumors and normal brain,” Experimental and Toxicologic Pathology, vol. 44, no. 6, pp. 317–324, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Portoukalian, M. David, M. Richard, and P. Gain, “Shedding of GD2 ganglioside in patients with retinoblastoma,” International Journal of Cancer, vol. 53, no. 6, pp. 948–951, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kailayangiri, B. Altvater, J. Meltzer et al., “The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting,” British Journal of Cancer, vol. 106, no. 6, pp. 1123–1133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Shibuya, K. Hamamura, H. Hotta et al., “Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3,” Cancer Science, vol. 103, no. 9, pp. 1656–1664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. V. L. Battula, Y. Shi, K. W. Evans et al., “Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis,” The Journal of Clinical Investigation, vol. 122, no. 6, pp. 2066–2078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. M. Phillips, W. H. McBride, and F. Pajonk, “The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation,” Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777–1785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. Cheever, J. P. Allison, A. S. Ferris et al., “The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research,” Clinical Cancer Research, vol. 15, no. 17, pp. 5323–5337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Saito, R. K. Yu, and N.-K. V. Cheung, “Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell,” Biochemical and Biophysical Research Communications, vol. 127, no. 1, pp. 1–7, 1985. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D. Gillies, K.-M. Lo, and J. Wesolowski, “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,” Journal of Immunological Methods, vol. 125, no. 1-2, pp. 191–202, 1989. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Mujoo, T. J. Kipps, H. M. Yang et al., “Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18,” Cancer Research, vol. 49, no. 11, pp. 2857–2861, 1989. View at Google Scholar · View at Scopus
  30. K. Mujoo, D. A. Cheresh, H. M. Yang, and R. A. Reisfeld, “Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth,” Cancer Research, vol. 47, no. 4, pp. 1098–1104, 1987. View at Google Scholar · View at Scopus
  31. Y. Zeng, S. Fest, R. Kunert et al., “Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice,” Molecular Immunology, vol. 42, no. 11, pp. 1311–1319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. S. Sorkin, M. Otto, W. M. Baldwin III et al., “Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia,” Pain, vol. 149, no. 1, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. N.-K. V. Cheung, H. Guo, J. Hu, D. V. Tassev, and I. Y. Cheung, “Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo,” OncoImmunology, vol. 1, no. 4, pp. 477–486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Dhillon, “Dinutuximab: first global approval,” Drugs, vol. 75, no. 8, pp. 923–927, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Yuki, M. Yamada, Y. Tagawa, H. Takahashi, and S. Handa, “Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy,” Journal of the Neurological Sciences, vol. 149, no. 2, pp. 127–130, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Siebert, C. Eger, D. Seidel et al., “Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2,” mAbs, vol. 8, no. 3, pp. 604–616, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung, “Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1168–1174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. N. Lode, N. Sibert, and C. Eger, “Interleukin-2 adds toxicity but not measurable activity in relapsed/refractory neuroblastoma patients treated with long term infusion of anti-GD2 antibody ch14.18/CHO,” Pediatric Blood Cancer, vol. 62, Abstract PD-057, 2015. View at Google Scholar
  39. N. Alvarez-Rueda, A. Desselle, D. Cochonneau et al., “A monoclonal antibody to O-Acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity,” PLoS ONE, vol. 6, no. 9, Article ID e25220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. E. R. Sjoberg, A. E. Manzi, K.-H. Khoo, A. Dell, and A. Varki, “Structural and immunological characterization of O-acetylated GD2: evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells,” Journal of Biological Chemistry, vol. 267, no. 23, pp. 16200–16211, 1992. View at Google Scholar · View at Scopus
  41. A. Varki, “Diversity in the sialic acids,” Glycobiology, vol. 2, no. 1, pp. 25–40, 1992. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Bardor, D. H. Nguyen, S. Diaz, and A. Varki, “Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells,” Journal of Biological Chemistry, vol. 280, no. 6, pp. 4228–4237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. H. C. Siebert, C. W. von der Lieth, X. Dong et al., “Molecular dynamics-derived conformation and intramolecular interaction analysis of the N-acetyl-9-O-acetylneuraminic acid-containing ganglioside GD1a and NMR-based analysis of its binding to a human polyclonal immunoglobulin G fraction with selectivity for O-acetylated sialic acids,” Glycobiology, vol. 6, no. 6, pp. 561–572, 1996. View at Google Scholar
  44. A. Varki and S. Diaz, “The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups,” Analytical Biochemistry, vol. 137, no. 1, pp. 236–247, 1984. View at Publisher · View at Google Scholar · View at Scopus
  45. J. P. Kamerling, R. Schauer, A. K. Shukla, S. Stoll, H. Van Halbeek, and J. F. Vliegenthart, “Migration of O-acetyl groups in N,O-acetylneuraminic acids,” European Journal of Biochemistry, vol. 162, no. 3, pp. 601–607, 1987. View at Publisher · View at Google Scholar
  46. J. Thurin, M. Herlyn, O. Hindsgaul et al., “Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-G(D3),” Journal of Biological Chemistry, vol. 260, no. 27, pp. 14556–14563, 1985. View at Google Scholar · View at Scopus
  47. G. K. Ostrander, M. Bozlee, M. Fukuda et al., “Isolation and characterization of the major glycosphingolipids from the liver of the rainbow trout (Oncorhynchus mykiss): identification of an abundant source of 9-O-acetyl GD3,” Archives of Biochemistry and Biophysics, vol. 284, no. 2, pp. 413–421, 1991. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Ren, T. Ariga, J. N. Scarsdale et al., “Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3,” Journal of Lipid Research, vol. 34, no. 9, pp. 1565–1572, 1993. View at Google Scholar · View at Scopus
  49. A. E. Manzi, E. R. Sjoberg, S. Diaz, and A. Varki, “Biosynthesis and turnover of O-acetyl and N-acetyl groups in the gangliosides of human melanoma cells,” The Journal of Biological Chemistry, vol. 265, no. 22, pp. 13091–13103, 1990. View at Google Scholar · View at Scopus
  50. S. Ruan and K. O. Lloyd, “Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns,” Cancer Research, vol. 52, no. 20, pp. 5725–5731, 1992. View at Google Scholar · View at Scopus
  51. S. Yamashiro, S. Ruan, K. Furukawa et al., “Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines,” Cancer Research, vol. 53, no. 22, pp. 5395–5400, 1993. View at Google Scholar · View at Scopus
  52. K. Furukawa, H. Soejima, N. Niikawa, H. Shiku, and K. Furukawa, “Genomic organization and chromosomal assignment of the human β1,4-N- acetylgalactosaminyltransferase gene. Identification of multiple transcription units,” Journal of Biological Chemistry, vol. 271, no. 34, pp. 20836–20844, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Stoddart, Y. Zhang, and C. J. Paige, “Molecular cloning of the cDNA encoding a murine sialic acid-specific 9-O-acetylesterase and RNA expression in cells of hematopoietic and non-hematopoietic origin,” Nucleic Acids Research, vol. 24, no. 20, pp. 4003–4008, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. M. J. Guimarães, J. F. Bazan, J. Castagnola et al., “Molecular cloning and characterization of lysosomal sialic acid O-acetylesterase,” The Journal of Biological Chemistry, vol. 271, no. 23, pp. 13697–13705, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Schauer, M. Wember, and C. F. Do Amaral, “Synthesis of CMP-glycosides of radioactive N-acetyl-,N-glycoloyl-,N-acetyl-7-O-acetyl- and N-acetyl-8-O-acetylneuraminic acids by CMP-sialate synthase from bovine submaxillary glands,” Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, vol. 353, no. 1, pp. 883–886, 1972. View at Publisher · View at Google Scholar · View at Scopus
  56. H. H. Higa, C. Butor, S. Diaz, and A. Varki, “O-Acetylation and de-O-acetylation of sialic acids. O-Acetylation of sialic acids in the rat liver Golgi apparatus involves an acetyl intermediate and essential histidine and lysine residues—a transmembrane reaction?” Journal of Biological Chemistry, vol. 264, no. 32, pp. 19427–19434, 1989. View at Google Scholar · View at Scopus
  57. K. Ogura, K. Nara, Y. Watanabe, K. Kohno, T. Tai, and Y. Sanai, “Cloning and expression of cDNA for O-acetylation of GD3 ganglioside,” Biochemical and Biophysical Research Communications, vol. 225, no. 3, pp. 932–938, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Kanamori, J. Nakayama, M. N. Fukuda et al., “Expression cloning and characterization of a cDNA encoding a novel membrane protein required for the formation of O-acetylated ganglioside: a putative acetyl-CoA transporter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 2897–2902, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. W.-X. Shi, R. Chammas, and A. Varki, “Induction of sialic acid 9-O-acetylation by diverse gene products: implications for the expression cloning of sialic acid O-acetyltransferases,” Glycobiology, vol. 8, no. 2, pp. 199–205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Satake, H. Y. Chen, and A. Varki, “Genes modulated by expression of GD3 synthase in Chinese hamster ovary cells: evidence that the Tis21 gene is involved in the induction of GD3 9-O-acetylation,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 7942–7948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Furukawa, W. Aixinjueluo, T. Kasama et al., “Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21,” Journal of Neurochemistry, vol. 105, no. 3, pp. 1057–1066, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Vandamme-Feldhaus and R. Schauer, “Characterization of the enzymatic 7-O-acetylation of sialic acids and evidence for enzymatic O-acetyl migration from C-7 to C-9 in bovine submandibular gland,” Journal of Biochemistry, vol. 124, no. 1, pp. 111–121, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Arming, D. Wipfler, J. Mayr et al., “The human Cas1 protein: a sialic acid-specific O-acetyltransferase?” Glycobiology, vol. 21, no. 5, pp. 553–564, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. A.-M. T. Baumann, M. J. G. Bakkers, F. F. R. Buettner et al., “9-O-Acetylation of sialic acids is catalysed by CASD1 via a covalent acetyl-enzyme intermediate,” Nature Communications, vol. 6, article 7673, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. J. N. Ye and N.-K. V. Cheung, “A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies,” International Journal of Cancer, vol. 50, no. 2, pp. 197–201, 1992. View at Publisher · View at Google Scholar · View at Scopus
  66. E. R. Sjoberg and A. Varki, “Kinetic and spatial interrelationships between ganglioside glycosyltransferases and O-acetyltransferase(s) in human melanoma cells,” Journal of Biological Chemistry, vol. 268, no. 14, pp. 10185–10196, 1993. View at Google Scholar · View at Scopus
  67. C. Butor, S. Diaz, and A. Varki, “High level O-acetylation of sialic acids on N-linked oligosaccharides of rat liver membranes: differential subcellular distribution of 7- and 9-O-acetyl groups and of enzymes involved in their regulation,” Journal of Biological Chemistry, vol. 268, no. 14, pp. 10197–10206, 1993. View at Google Scholar · View at Scopus
  68. H. Araujo, M. Menezes, and R. Mendez-Otero, “Blockage of 9-O-acetyl gangliosides induces microtubule depolymerization in growth cones and neurites,” European Journal of Cell Biology, vol. 72, no. 3, pp. 202–213, 1997. View at Google Scholar · View at Scopus
  69. A. Varki, F. Hooshmand, S. Diaz, N. M. Varki, and S. M. Hedrick, “Developmental abnormalities in transgenic mice expressing a sialic acid-specific 9-O-acetylesterase,” Cell, vol. 65, no. 1, pp. 65–74, 1991. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Kniep, J. Peter-Katalinić, W. Flegel, H. Northoff, and E. P. Rieber, “CDw 60 antibodies bind to acetylated forms of ganglioside GD3,” Biochemical and Biophysical Research Communications, vol. 187, no. 3, pp. 1343–1349, 1992. View at Publisher · View at Google Scholar · View at Scopus
  71. D. A. Fox, X. He, A. Abe et al., “The T lymphocyte structure CD60 contains a sialylated carbohydrate epitope that is expressed on both gangliosides and glycoproteins,” Immunological Investigations, vol. 30, no. 2, pp. 67–85, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Vater, B. Kniep, H.-J. Groß, C. Claus, W. Dippold, and R. Schwartz-Albiez, “The 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B lymphocytes,” Immunology Letters, vol. 59, no. 3, pp. 151–157, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. J. B. Higgs, W. Zeldes, K. Kozarsky et al., “A novel pathway of human T lymphocyte activation: identification by a monoclonal antibody generated against a rheumatoid synovial T cell line,” Journal of Immunology, vol. 140, no. 11, pp. 3758–3765, 1988. View at Google Scholar · View at Scopus
  74. K. Mukherjee, A. K. Chava, C. Mandal et al., “O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia,” Journal of Cellular Biochemistry, vol. 105, no. 3, pp. 724–734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Malisan, L. Franchi, B. Tomassini et al., “Acetylation suppresses the proapoptotic activity of GD3 ganglioside,” Journal of Experimental Medicine, vol. 196, no. 12, pp. 1535–1541, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Birklé, S. Ren, A. Slominski, G. Zeng, L. Gao, and R. K. Yu, “Down-regulation of the expression of O-acetyl-GD3 by the O- acetylesterase cDNA in hamster melanoma cells: effects on cellular proliferation, differentiation, and melanogenesis,” Journal of Neurochemistry, vol. 72, no. 3, pp. 954–961, 1999. View at Publisher · View at Google Scholar · View at Scopus
  77. S. M. Birks, J. O. Danquah, L. King, R. Vlasak, D. C. Gorecki, and G. J. Pilkington, “Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma,” Neuro-Oncology, vol. 13, no. 9, pp. 950–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Kniep, E. Kniep, N. Özkucur et al., “9-O-acetyl GD3 protects tumor cells from apoptosis,” International Journal of Cancer, vol. 119, no. 1, pp. 67–73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Parameswaran, M. Lim, A. Arutyunyan et al., “O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia,” Journal of Experimental Medicine, vol. 210, no. 4, pp. 805–819, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Cochonneau, M. Terme, A. Michaud et al., “Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo,” Cancer Letters, vol. 333, no. 2, pp. 194–204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Aixinjueluo, K. Furukawa, Q. Zhang et al., “Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis,” The Journal of Biological Chemistry, vol. 280, no. 33, pp. 29828–29836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Kowalczyk, M. Gil, I. Horwacik, Z. Odrowaz, D. Kozbor, and H. Rokita, “The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells,” Cancer Letters, vol. 281, no. 2, pp. 171–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. C.-Y. Tsao, F. Sabbatino, N.-K. V. Cheung et al., “Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells,” OncoImmunology, vol. 4, no. 8, Article ID e1023975, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Yoshida, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa, “An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun Terminal Kinase) activation,” Japanese Journal of Cancer Research, vol. 93, no. 7, pp. 816–824, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Yoshida, S. Fukumoto, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa, “Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis,” Cancer Research, vol. 61, pp. 4244–4252, 2001. View at Google Scholar
  86. C. M. Lynch, B. W. Hart, and I. S. Grewal, “Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies,” mAbs, vol. 1, no. 1, pp. 2–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Fleurence, D. Cochonneau, S. Fougeray et al., “Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  88. S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Research, vol. 63, no. 18, pp. 5821–5828, 2003. View at Google Scholar · View at Scopus
  89. T. Tanei, K. Morimoto, K. Shimazu et al., “Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers,” Clinical Cancer Research, vol. 15, no. 12, pp. 4234–4241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. R. Esparza, T. D. Azad, A. H. Feroze, S. S. Mitra, and S. H. Cheshier, “Glioblastoma stem cells and stem cell-targeting immunotherapies,” Journal of Neuro-Oncology, vol. 123, no. 3, pp. 449–457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Ozawa, M. Kotani, I. Kawashima, and T. Tai, “Generation of one set of monoclonal antibodies specific for b-pathway ganglio-series gangliosides,” Biochimica et Biophysica Acta, vol. 1123, no. 2, pp. 184–190, 1992. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Kotani, H. Ozawa, I. Kawashima, S. Ando, and T. Tai, “Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides,” Biochimica et Biophysica Acta, vol. 1117, no. 1, pp. 97–103, 1992. View at Publisher · View at Google Scholar · View at Scopus
  93. K. J. Lee, S. Mao, C. Sun et al., “Phage-display selection of a human single-chain Fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized GM3-carbohydrate antigen,” Journal of the American Chemical Society, vol. 124, no. 42, pp. 12439–12446, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Rojas, A. Pupo, S. Gómez, U. Krengel, and E. Moreno, “Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities,” ACS Chemical Biology, vol. 8, no. 2, pp. 376–386, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Cerato, S. Birkle, J. Portoukalian, A. Mezazigh, J.-F. Chatal, and J. Aubry, “Variable region gene segments of nine monoclonal antibodies specific to disialogangliosides (GD2, GD3) and their O-acetylated derivatives,” Hybridoma, vol. 16, no. 4, pp. 307–316, 1997. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Yuki, T. Miyatake, Y. Ichihashi, S. Sato, and T. Katagiri, “IgM anti-(GalNAc β1-4 Gal[3-2α NeuAc]β1-) antibody-mediated cytotoxicity in a patient with amyotrophic lateral sclerosis-like disorder,” Muscle and Nerve, vol. 15, no. 12, pp. 1371–1373, 1992. View at Google Scholar · View at Scopus
  97. M. Z. Ladjemi, “Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements,” Frontiers in Oncology, vol. 2, article 158, 2012. View at Publisher · View at Google Scholar
  98. A. Perez, E. S. Mier, N. S. Vispo, A. M. Vazquez, and R. P. Rodríguez, “A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells,” Molecular Immunology, vol. 39, no. 1-2, pp. 103–112, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Alfonso, A. Valdés-Zayas, E. R. Santiesteban et al., “A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients,” Clinical Cancer Research, vol. 20, no. 14, pp. 3660–3671, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. W. Cacciavillano, C. Sampor, C. Venier et al., “A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies,” Pediatric Blood and Cancer, vol. 62, no. 12, pp. 2120–2124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson, “Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer,” Cancer Research, vol. 65, no. 22, pp. 10562–10568, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick, “FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2885–2890, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. N. Tarek, J.-B. L. Luduec, M. M. Gallagher et al., “Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment,” Journal of Clinical Investigation, vol. 122, no. 9, pp. 3260–3270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Terme, M. Dorvillius, D. Cochonneau et al., “Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia,” PLoS ONE, vol. 9, no. 2, Article ID e87210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. N.-K. V. Cheung, H. Lazarus, F. D. Miraldi et al., “Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma,” Journal of Clinical Oncology, vol. 5, no. 9, pp. 1430–1440, 1987. View at Google Scholar · View at Scopus
  106. K. J. Curran, H. J. Pegram, and R. J. Brentjens, “Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions,” Journal of Gene Medicine, vol. 14, no. 6, pp. 405–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. M. H. Kershaw, J. A. Westwood, and P. K. Darcy, “Gene-engineered T cells for cancer therapy,” Nature Reviews Cancer, vol. 13, no. 8, pp. 525–541, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. S. L. Maude, N. Frey, P. A. Shaw et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” New England Journal of Medicine, vol. 371, no. 16, pp. 1507–1517, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. S. A. Grupp, M. Kalos, D. Barrett et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” New England Journal of Medicine, vol. 368, no. 16, pp. 1509–1518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. M. L. Davila, I. Riviere, X. Wang et al., “Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia,” Science Translational Medicine, vol. 6, no. 224, Article ID 224ra25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim et al., “Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor,” Journal of Clinical Oncology, vol. 33, no. 6, pp. 540–549, 2015. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Dotti, S. Gottschalk, B. Savoldo, and M. K. Brenner, “Design and development of therapies using chimeric antigen receptor-expressing T cells,” Immunological Reviews, vol. 257, no. 1, pp. 107–126, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Dotti, B. Savoldo, and M. Brenner, “Fifteen years of gene therapy based on chimeric antigen receptors: ‘are we nearly there yet?’,” Human Gene Therapy, vol. 20, no. 11, pp. 1229–1239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. B. Savoldo and G. Dotti, “Chimeric antigen receptors (CARs) from bench-to-bedside,” Immunology Letters, vol. 155, no. 1-2, pp. 40–42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. R. J. Brentjens, J.-B. Latouche, E. Santos et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” Nature Medicine, vol. 9, no. 3, pp. 279–286, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. R. J. Brentjens, E. Santos, Y. Nikhamin et al., “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5426–5435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. B. Savoldo, C. A. Ramos, E. Liu et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” Journal of Clinical Investigation, vol. 121, no. 5, pp. 1822–1826, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Rossig, J. G. Nuchtern, and M. K. Brenner, “Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma,” Medical and Pediatric Oncology, vol. 35, no. 6, pp. 692–695, 2000. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Rossig, C. M. Bollard, J. G. Nuchtern, D. A. Merchant, and M. K. Brenner, “Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes,” International Journal of Cancer, vol. 94, no. 2, pp. 228–236, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. M. A. Pule, B. Savoldo, G. D. Myers et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. C. U. Louis, B. Savoldo, G. Dotti et al., “Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma,” Blood, vol. 118, no. 23, pp. 6050–6056, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. M. A. Pulè, K. C. Straathof, G. Dotti, H. E. Heslop, C. M. Rooney, and M. K. Brenner, “A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells,” Molecular Therapy, vol. 12, no. 5, pp. 933–941, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. A. H. Long, W. M. Haso, J. F. Shern et al., “4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors,” Nature Medicine, vol. 21, no. 6, pp. 581–590, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. J. L. Davis, M. R. Theoret, Z. Zheng, C. H. J. Lamers, S. A. Rosenberg, and R. A. Morgan, “Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials,” Clinical Cancer Research, vol. 16, no. 23, pp. 5852–5861, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. M. C. Jensen, L. Popplewell, L. J. Cooper et al., “Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans,” Biology of Blood and Marrow Transplantation, vol. 16, no. 9, pp. 1245–1256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. C. H. J. Lamers, R. Willemsen, P. Van Elzakker et al., “Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells,” Blood, vol. 117, no. 1, pp. 72–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Hudecek, M.-T. Lupo-Stanghellini, P. L. Kosasih et al., “Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells,” Clinical Cancer Research, vol. 19, no. 12, pp. 3153–3164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Kuünkele, A. J. Johnson, L. S. Rolczynski et al., “Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell fas-FasL-dependent AICD,” Cancer Immunology Research, vol. 3, no. 4, pp. 368–379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Thomas, K. Straathof, N. Himoudi, J. Anderson, and M. Pule, “An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers,” PLoS ONE, vol. 11, no. 3, Article ID e0152196, 2016. View at Publisher · View at Google Scholar · View at Scopus
  130. B. Clémenceau, S. Valsesia-Wittmann, A.-C. Jallas et al., “In vitro and in vivo comparison of lymphocytes transduced with a human CD16 or with a chimeric antigen receptor reveals potential off-target interactions due to the IgG2 CH2-CH3 CAR-spacer,” Journal of Immunology Research, vol. 2015, Article ID 482089, 13 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Hombach, A. A. Hombach, and H. Abken, “Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response,” Gene Therapy, vol. 17, no. 10, pp. 1206–1213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 720–724, 1993. View at Publisher · View at Google Scholar · View at Scopus
  133. J. S. Bridgeman, R. E. Hawkins, S. Bagley, M. Blaylock, M. Holland, and D. E. Gilham, “The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex,” The Journal of Immunology, vol. 184, no. 12, pp. 6938–6949, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. M. C. Milone, J. D. Fish, C. Carpenito et al., “Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo,” Molecular Therapy, vol. 17, no. 8, pp. 1453–1464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Carpenito, M. C. Milone, R. Hassan et al., “Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3360–3365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. S. Tammana, X. Huang, M. Wong et al., “4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies,” Human Gene Therapy, vol. 21, no. 1, pp. 75–86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Guedan, X. Chen, A. Madar et al., “ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells,” Blood, vol. 124, no. 7, pp. 1070–1080, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. C. R. Y. Cruz, K. P. Micklethwaite, B. Savoldo et al., “Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study,” Blood, vol. 122, no. 17, pp. 2965–2973, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Gattinoni, S. E. Finkelstein, C. A. Klebanoff et al., “Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells,” The Journal of Experimental Medicine, vol. 202, no. 7, pp. 907–912, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. C. A. Klebanoff, L. Gattinoni, and N. P. Restifo, “Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?” Journal of Immunotherapy, vol. 35, no. 9, pp. 651–660, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. C. A. Klebanoff, L. Gattinoni, P. Torabi-Parizi et al., “Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9571–9576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. L. S. Metelitsa, “Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans,” Clinical Immunology, vol. 140, no. 2, pp. 119–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Heczey, D. Liu, A. Courtney et al., “NKT cells as a novel platform for cancer immunotherapy with chimeric antigen receptors,” in Proceedings of the American Society of Gell and Cell Therapy Annual Meeting, Salt Lake City, Utah, USA, 2013.
  144. D. Liu, L. Song, J. Wei et al., “IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity,” Journal of Clinical Investigation, vol. 122, no. 6, pp. 2221–2233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. L. S. Metelitsa, H.-W. Wu, H. Wang et al., “Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2,” Journal of Experimental Medicine, vol. 199, no. 9, pp. 1213–1221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  146. L. Song, S. Asgharzadeh, J. Salo et al., “Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1524–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Heczey, D. Liu, G. Tian et al., “Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy,” Blood, vol. 124, no. 18, pp. 2824–2833, 2014. View at Publisher · View at Google Scholar · View at Scopus